Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Sujuan Yuan

Efficacy and Safety of Adding an Agent to Bevacizumab/Taxane Regimens for the First-Line Treatment of Her2-Negative Patients With Locally Recurrent or Metastatic Breast Cancer: Results From Seven Randomized Controlled Trials

OncoTargets and Therapy
OncologyPharmacology
2016English

Related publications

Capecitabine (Cap) Combined With Bevacizumab (Bev) With or Without Vinorelbine (Vin) in First-Line Metastatic Breast Cancer (MBC): First Safety Results From the Randomized CARIN Trial.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

The Addition of Bevacizumab in the First-Line Treatment for Metastatic Colorectal Cancer: An Updated Meta-Analysis of Randomized Trials

Oncotarget
Oncology
2017English

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer
Oncology
2020English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Assessing the Tolerability and Efficacy of First-Line Chemotherapy in Elderly Patients With Metastatic HER2−ve Breast Cancer

ecancermedicalscience
Cancer ResearchOncology
2019English

First-Line Single-Agent Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer With Poor Performance Status

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2012English

Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2016English

FOLFIRI® and Bevacizumab in First-Line Treatment for Colorectal Cancer Patients: Safety, Efficacy and Genetic Polymorphisms

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2014English

Dual HER2 Blockade Versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Oncology
Oncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy